This is one of the best overviews I've come across on this topic!
The emergence of microdosing protocols for GLP-1 medications is another area generating significant clinical interest. Some practitioners are exploring whether lower doses can provide meaningful metabolic benefits with a reduced side effect burden, particularly for patients who struggle with the nausea and gastrointestinal discomfort that can accompany standard titration schedules. Compounded formulations have also entered the conversation, though questions around quality control and bioequivalence remain important considerations. The peptide therapy space is evolving rapidly, and staying current with the literature is essential for both patients and prescribers.
For anyone managing type 2 diabetes alongside obesity, the selection of a GLP-1 receptor agonist over other antidiabetic agents often…
This is one of the best overviews I've come across on this topic!
The emergence of microdosing protocols for GLP-1 medications is another area generating significant clinical interest. Some practitioners are exploring whether lower doses can provide meaningful metabolic benefits with a reduced side effect burden, particularly for patients who struggle with the nausea and gastrointestinal discomfort that can accompany standard titration schedules. Compounded formulations have also entered the conversation, though questions around quality control and bioequivalence remain important considerations. The peptide therapy space is evolving rapidly, and staying current with the literature is essential for both patients and prescribers.
For anyone managing type 2 diabetes alongside obesity, the selection of a GLP-1 receptor agonist over other antidiabetic agents often…